Bluebird Bio Inc
![Bluebird Bio Inc](https://api.admiralmarkets.com/trade_icons/bright-128/BLUE.png)
Suletud
0.52 -7.14
Ülevaade
Aktsiahinna muutus
24h
Min
0.51
Max
0.53
Sissetulek | -72M |
---|---|
Müük | 12M |
Aktsiakasum | -0.66 |
Kasumimarginaal | -578.849 |
EBITDA | -84M |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +686.79 upside |
Järgmine tulemuste avaldamine | 5. nov 2024 |
---|
Turukapital | 5.7M 240M |
---|---|
Eelmine avamishind | 7.66 |
Eelmine sulgemishind | 0.52 |
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Bluebird Bio Inc Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Bluebird Bio Inc Prognoos
Hinnasiht
By TipRanks
686.79% tõus
12 kuu keskmine prognoos
Keskmine 4.17 USD 686.79%
Kõrge 6 USD
Madal 3 USD
Põhineb 10 Wall Streeti analüütiku instrumendi Bluebird Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
EBITDA
Ärikasum
$
Ettevõttest Bluebird Bio Inc
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.